RP-116 / ViroCure - LARVOL DELTA

Virocure, Virus Research Results for Anticancer Vaccine Adopted as Cover Paper [Google translation] (Mol Ther Oncolytics, Hankyung) - "ViroCure announced on the 7th that its paper on the characteristics of RP116...was selected as the cover paper for the September issue of Molecular Therapy Oncology...RP116 modified reovirus for anticancer vaccines has the characteristic of effectively evading neutralizing antibodies against wild-type reovirus. Therefore, it is expected that cancer patients who have been infected with wild-type reovirus in the past will also be able to expect long-term high anticancer effects when administered RP116. The RP116 modified reovirus also has the advantage of not showing side effects or toxicity even in immunocompromised mice, so it can be safely used in cancer patients with weakened immunity....ViroCure holds a US material patent for RP116, and applied for a patent as a new anticancer vaccine platform using it, and the patent was registered by the Korean Intellectual Property Office on October 4, 2024. It has also applied for international patents in the US, Europe, Japan, China, etc."

Patent • Preclinical • Oncology • Solid Tumor

Virocure, Virus Research Results for Anticancer Vaccine Adopted as Cover Paper [Google translation] (Mol Ther Oncolytics, Hankyung) - "ViroCure announced on the 7th that its paper on the characteristics of RP116...was selected as the cover paper for the September issue of Molecular Therapy Oncology...RP116 modified reovirus for anticancer vaccines has the characteristic of effectively evading neutralizing antibodies against wild-type reovirus. Therefore, it is expected that cancer patients who have been infected with wild-type reovirus in the past will also be able to expect long-term high anticancer effects when administered RP116. The RP116 modified reovirus also has the advantage of not showing side effects or toxicity even in immunocompromised mice, so it can be safely used in cancer patients with weakened immunity....ViroCure holds a US material patent for RP116, and applied for a patent as a new anticancer vaccine platform using it, and the patent was registered by the Korean Intellectual Property Office on October 4, 2024. It has also applied for international patents in the US, Europe, Japan, China, etc."

Patent • Preclinical • Oncology • Solid Tumor